Revive Therapeutics Ltd (RVV) to Release Quarterly Earnings on Wednesday
TRADEMARK VIOLATION NOTICE: This piece of content was first reported by American Banking News and is the property of of American Banking News. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of US and international copyright & trademark law. The original version of this piece of content can be read at https://www.americanbankingnews.com/2017/10/11/revive-therapeutics-ltd-rvv-to-release-quarterly-earnings-on-wednesday.html.
About Revive Therapeutics
Revive Therapeutics Ltd (Revive) is engaged in commercializing treatments for rare diseases, such as Cystinuria, Wilson’s disease and Rett syndrome. The Company has completed a Phase II-A study for acute gout flares in the United States. The Company’s business model focuses on finding new uses of old drugs with the objective of finding a partner or partners to bring the new use drug to the marketplace.
Receive News & Ratings for Revive Therapeutics Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revive Therapeutics Ltd and related companies with MarketBeat.com's FREE daily email newsletter.